Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy : Future Perspectives |
Autore | Vermehren Charlotte |
Pubbl/distr/stampa | Basel, : MDPI Books, 2022 |
Descrizione fisica | 1 electronic resource (224 p.) |
Soggetto topico |
Medicine
Pharmaceutical industries |
Soggetto non controllato |
acute kidney injury
early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged aged, 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Altri titoli varianti | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
Record Nr. | UNINA-9910595072903321 |
Vermehren Charlotte
![]() |
||
Basel, : MDPI Books, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Treatment Strategies and Survival Outcomes in Breast Cancer |
Autore | Cheung Kwok-Leung |
Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
Descrizione fisica | 1 electronic resource (264 p.) |
Soggetto non controllato |
relative survival
young women cancer treatment fulvestrant lapatinib tumor biology antihormone therapy mastectomy aromatase inhibitors chemotherapy serum biomarker cyclin E anthracycline resistance zero-inflated Poisson regression model lymph-node ratio CHEK2 comparative effectiveness breast-conserving therapy taxane sensitivity liquid biopsy HER2 c-erbB2 colorectal cancer infiltrating breast cancer survival exercise characteristics lactate dehydrogenase biomarker breast cancer survivors BRCA disease-free survival PIK3CA metastatic breast cancer cell-free DNA invasive breast cancer radiotherapy Metformin social well-being gene expression contralateral breast cancer basal-like breast cancer LMK-235 Src kinase HER2/neu LKB1 Older women LDH mutation carriers stage IV mammography screening NCDB cMet SEER pertuzumab physical function outcome ribociclib older patients geriatric oncology metastatic overdiagnosis next-generation sequencing abemaciclib Endocrine therapy monitoring metastatic breast cancer breast cancer circulating tumor cells Breast Cancer PALB2 histone deacetylase prognosis physical activity trastuzumab ductal carcinoma in situ contralateral prophylactic mastectomy ERCC1 family history T-DM1 ATM advanced breast cancer incidence palbociclib HDAC5 inhibitors APOBEC3B |
ISBN | 3-03928-759-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910404084403321 |
Cheung Kwok-Leung
![]() |
||
MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|